Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy

PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%–20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence of FN while using this regimen was obtained mostly from Western breast cancer patients,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Breast Cancer
Main Authors: Kim, Chang Gon, Sohn, Joohyuk, Chon, Hongjae, Kim, Joo Hoon, Heo, Su Jin, Cho, Hyunsoo, Kim, In Jung, Kim, Seung Il, Park, Seho, Park, Hyung Seok, Kim, Gun Min
Formato: Artigo
Idioma:Inglês
Publicado: Korean Breast Cancer Society 2016
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4822110/
https://ncbi.nlm.nih.gov/pubmed/27064666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2016.19.1.76
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares